Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00392925 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 177
- Enrollment target
NCT00392925 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 177 participants.
The verdict
NCT00392925, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 177 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability, and effect on body weight of leptin, injected subcutaneously, in combination with pramlintide, injected subcutaneously.
Interventions
- DRUG metreleptin
- DRUG pramlintide acetate 360 mcg
- DRUG placebo-pramlintide 600 uL
- DRUG placebo-metreleptin 1 mL
- DRUG Pramlintide acetate 180 mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 177 participants |
| Start Date | 2006-10 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00392925
The ClinicalTrials.gov registry entry for NCT00392925 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 177 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which metreleptin is the first listed.
NCT00392925 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00392925 about?
NCT00392925 is a clinical study titled "A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects". This study will evaluate the safety, tolerability, and effect on body weight of leptin, injected subcutaneously, in combination with pramlintide, injected subcutaneously.
What is the current status of trial NCT00392925?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 177 participants. The study started on 2006-10. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00392925?
The interventions under investigation include: metreleptin (DRUG), pramlintide acetate 360 mcg (DRUG), placebo-pramlintide 600 uL (DRUG), placebo-metreleptin 1 mL (DRUG), Pramlintide acetate 180 mcg (DRUG).
Who is sponsoring clinical trial NCT00392925?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.